- Innate Pharma to highlight IPH4502, its lead Nectin-4
Antibody Drug Conjugate (ADC) program at clinical stage
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) will host an event for
institutional investors and analysts dedicated to its Antibody-Drug
Conjugate (ADC) strategy, and particularly Nectin-4, the target of
its lead antibody-drug candidate program, IPH4502. The event will
be held in New York in a hybrid format on Wednesday, February 5,
2025, from 10:00 a.m. to 12:00 p.m. EDT.
“As we just updated our strategy with a focus on our ANKET®
platform and ADC programs, this meeting will be an opportunity to
share the latest scientific and clinical advancements related to
Nectin-4 and its potential in cancer treatment,” said Jonathan
Dickinson, Chief Executive Officer of Innate Pharma
Event details:
- Date: February 5, 2025, from 10:00 a.m. to 12:00 p.m.
EDT
- Registration: If you would like to attend the event,
please register at this link:
https://form.jotform.com/250134241556348
For those who are unable to attend in person, a live webcast and
replay will be on Innate Pharma’s website at:
https://www.innate-pharma.com.
About IPH4502
IPH4502 is a novel and differentiated topoisomerase I inhibitor
ADC designed to precisely target Nectin-4, a cell adhesion molecule
that is overexpressed in several types of solid tumors, including
urothelial carcinoma, where Nectin-4 expression is highest, breast
cancer, non-small cell lung cancer and gastro-intestinal
cancer.
In non-clinical models, IPH45 is well tolerated and shows
anti-tumor activity in vitro and in vivo.
In September 2024, the U.S Food and Drug Administration (FDA)
has cleared its investigational new drug (IND) application to
initiate a Phase 1 clinical study of IPH4502.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through three therapeutic approaches: multi-specific NK Cell
Engagers via its ANKET® (Antibody-based NK cell
Engager Therapeutics) proprietary platform and
Antibody Drug Conjugates (ADC) and monoclonal antibodies
(mAbs).
Innate’s portfolio includes several ANKET® drug candidates to
address multiple tumor types as well as IPH4502, a differentiated
ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb
lacutamab is developed in advanced form of cutaneous T cell
lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb
monalizumab is developed with AstraZeneca in non-small cell lung
cancer.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com and
follow us on LinkedIn and X.
Information about Innate Pharma shares
ISIN code Ticker
code LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995. The
use of certain words, including “anticipate,” “believe,” “can,”
“could,” “estimate,” “expect,” “may,” “might,” “potential,”
“expect” “should,” “will,” or the negative of these and similar
expressions, is intended to identify forward-looking statements.
Although the Company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s reliance on third parties to manufacture its product
candidates, the Company’s commercialization efforts and the
Company’s continued ability to raise capital to fund its
development. For an additional discussion of risks and
uncertainties, which could cause the Company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors (“Facteurs de Risque") section of the Universal
Registration Document filed with the French Financial Markets
Authority (“AMF”), which is available on the AMF website
http://www.amf-france.org or on Innate Pharma’s website, and public
filings and reports filed with the U.S. Securities and Exchange
Commission (“SEC”), including the Company’s Annual Report on Form
20-F for the year ended December 31, 2023, and subsequent filings
and reports filed with the AMF or SEC, or otherwise made public by
the Company. References to the Company’s website and the AMF
website are included for information only and the content contained
therein, or that can be accessed through them, are not incorporated
by reference into, and do not constitute a part of, this press
release.
In light of the significant uncertainties in these
forward-looking statements, you should not regard these statements
as a representation or warranty by the Company or any other person
that the Company will achieve its objectives and plans in any
specified time frame or at all. The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250120956658/en/
Investors Innate
Pharma Henry Wheeler Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Innate Pharma (NASDAQ:IPHA)
過去 株価チャート
から 12 2024 まで 1 2025
Innate Pharma (NASDAQ:IPHA)
過去 株価チャート
から 1 2024 まで 1 2025
